Pharmaceutical treatments to prevent recurrence of endometriosis following surgery: A model-based economic evaluation

BMJ Open

Volumn 6, Issue 4, 2016, Pages

  Sanghera, Sabina ^a,b   Barton, Pelham ^a   Bhattacharya, Siladitya ^c   Horne, Andrew W ^d   Roberts, Tracy Elizabeth ^a  

^a UNIVERSITY OF BIRMINGHAM   (United Kingdom)

^b UNIVERSITY OF BRISTOL   (United Kingdom)

^c UNIVERSITY OF ABERDEEN   (United Kingdom)

^d UNIVERSITY OF EDINBURGH   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

COMBINED ORAL CONTRACEPTIVE PILL; DEPOT MEDROXYPROGESTERONE ACETATE; LEVONORGESTREL; MEDROXYPROGESTERONE ACETATE; ORAL CONTRACEPTIVE AGENT; UNCLASSIFIED DRUG; CONTRACEPTIVE AGENT; TRANEXAMIC ACID;

ARTICLE; ECONOMIC EVALUATION; ENDOMETRIOSIS; FEMALE; FOLLOW UP; HEALTH CARE COST; HIDDEN MARKOV MODEL; HUMAN; LEVONORGESTREL RELEASING INTRAUTERINE SYSTEM; MAJOR CLINICAL STUDY; MODEL; NATIONAL HEALTH SERVICE; QUALITY ADJUSTED LIFE YEAR; RECURRENT DISEASE; SENSITIVITY ANALYSIS; COMPARATIVE STUDY; COMPLICATION; COST BENEFIT ANALYSIS; ECONOMIC MODEL; ECONOMICS; INTRAUTERINE CONTRACEPTIVE DEVICE; PRIMARY HEALTH CARE; SECONDARY PREVENTION; TREATMENT OUTCOME;

CONTRACEPTIVE AGENTS, FEMALE; COST-BENEFIT ANALYSIS; ENDOMETRIOSIS; FEMALE; HUMANS; INTRAUTERINE DEVICES, MEDICATED; LEVONORGESTREL; MODELS, ECONOMIC; PRIMARY HEALTH CARE; QUALITY-ADJUSTED LIFE YEARS; SECONDARY PREVENTION; TRANEXAMIC ACID; TREATMENT OUTCOME;

EID: 84971373017     PISSN: None     EISSN: 20446055     Source Type: Journal    
DOI: 10.1136/bmjopen-2015-010580     Document Type: Article

References (20)

1. Kennedy S, Bergqvist A, Chapron C, et al. ESHRE guideline for the diagnosis and treatment of endometriosis. Hum Reprod 2005;20:2698-704.
2. Eskenazi B, Warner ML. Epidemiology of endometriosis. Obstet Gynecol Clin North Am 1997;24:235-58.
3. ESHRE-European Society of Human Reproduction and Embryology. Management of women with endometriosis. ESHRE Guideline development group. 2013. http://www.eshre.eu/~/media/Files/ESHRE%20guideline%20on%20endometriosis%202013%20v1.pdf.
4. De Graaff AA, D'Hooghe TM, Dunselman GAJ, et al. The significant effect of endometriosis on physical, mental and social wellbeing: results from an international cross-sectional survey. Hum Reprod 2013;28:2677-85.
5. Garry R. The effectiveness of laparoscopic excision of endometriosis. Curr Opin Obstet Gynecol 2004;16:299-303.
6. Abou-Setta AM, Al-Inany HG, Farquhar CM. Levonorgestrel-releasing intrauterine device (LNG-IUD) for symptomatic endometriosis following surgery. Cochrane Database Syst Rev 2006;(4):CD005072.
7. Daniels JP, Clark TJ, Bhattacharya S. BSGE Survey of current post-operative hormonal treatment for Endometriosis. 2012.
8. Sculpher MJ, Claxton K, Drummond M, et al. Whither trial-based economic evaluation for health care decision making? Health Econ 2006;15:677-87.
9. Nnoaham KE, Hummelshoj L, Webster P, et al. Impact of endometriosis on quality of life and work productivity: A multicenter study across ten countries. Fertil Steril 2011;96:366-73.
10. Crosignani PG, Luciano A, Ray A. Subcutaneous depot medroxyprogesterone acetate versus leuprolide acetate in the treatment of endometriosis-associated pain. Hum Reprod 2006;21:248-56.
11. Sesti F, Pietropolli A, Capozzolo T, et al. Hormonal suppression treatment or dietary therapy versus placebo in the control of painful symptoms after conservative surgery for endometriosis stage III-IV. A randomized comparative trial. Fertil Steril 2007;88:1541-7.
12. Bayoglu Tekin Y, Dilbaz B, Altinbas SK, et al. Postoperative medical treatment of chronic pelvic pain related to severe endometriosis: levonorgestrel-releasing intrauterine system versus gonadotropinreleasing hormone analogue. Fertil Steril 2011;95:492-6.
13. Guzick DS, Huang LS, Broadman BA, et al. Randomized trial of leuprolide versus continuous oral contraceptives in the treatment of endometriosis-associated pelvic pain. Fertil Steril 2011;95:1568-73.
14. Tanmahasamut P, Rattanachaiyanont M, Angsuwathana S, et al. Postoperative levonorgestrel-releasing intrauterine system for pelvic endometriosis-related pain: A randomized controlled trial. Obstet Gynecol 2012;119:519-26.
15. Briggs A, Claxton K, Sculpher M. Decision modelling in health economic evaluation. Oxford: Oxford University Press, 2006.
16. Sanghera S, Roberts TE, Barton P, et al. Levonorgestrel-releasing intrauterine system vs. usual medical treatment for menorrhagia: An economic evaluation alongside a randomised controlled trial. PLoS ONE 2014;9:e91891.
17. Curtis L. Unit costs of health and social care. Personal Social Service Research Unit, 2013.
18. Joint Formulary Committee. British National Formulary 66. BMJ Group & Pharmaceutical Press, 2013.
19. Roberts TE, Tsourapas A, Middleton LJ, et al. Hysterectomy, endometrial ablation, and levonorgestrel releasing intrauterine system (Mirena) for treatment of heavy menstrual bleeding: cost effectiveness analysis. BMJ 2011;342:d2202.
20. National Institute of Health and Clinical Excellence. Guide to the methods of technology appraisal. London: National Institute of Health and Clinical Excellence, 2008.